1. Search Result

Search Result

Targets Recommended: CRISPR/Cas9

Results for "140651-18-9" in MCE Product Catalog:

Cat. No. Product Name Target Research Areas
  • HY-100429

    CDK Cancer
    CAN508 is a potent, ATP-competitive CDK9/cyclin T1 inhibitor with an IC50 of 0.35 μM. CAN508 exhibits a 38-fold selectivity for CDK9/cyclin T over other CDK/cyclin complexes. Antitumor activity.